{
  "paper_metadata": {
    "pmid": "38323364",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on the BRCA2 variant c.968dupT, including clinical significance, patient demographics, penetrance data, and functional information."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.968dupT",
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "15-year-old male",
        "phenotype": "pericardial synovial sarcoma"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 1,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 15,
          "age_at_onset": null,
          "age_at_diagnosis": 15,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "pericardial synovial sarcoma",
          "evidence_sentence": "Here, we first present a PSS patient who experienced disease relapse, BRCA2 mutation was identified by next\u2010generation sequencing (NGS) and had a robust response to pazopanib plus nivolumab with PFS of 14 months."
        }
      ],
      "functional_data": {
        "summary": "The insertion of 'T' leads to a frameshift mutation resulting in a new nonsense mutation, causing loss of amino acids from code 326 to code 3419.",
        "assays": [
          "next-generation sequencing",
          "protein analysis"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The variant has not previously been reported in PSS.",
      "key_quotes": [
        "BRCA2 c.968dupT has not previously been reported in PSS and its response to targeted combination immunotherapy are not well characterized.",
        "The patient in our study was treated with pazopanib plus nivolumab with a partial response of up to 14 months."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data regarding the BRCA2 variant was extracted successfully."
  }
}